BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

...commercial milestones. It acquired oncolytic virus company ViraTherapeutics GmbH...
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...with smaller deals for European biotechs in recent years. It acquired Austrian oncolytic virus developer ViraTherapeutics GmbH...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...the executive director of a life sciences consulting firm; Müller was head of CMC at ViraTherapeutics GmbH...
BioCentury | Aug 21, 2019
Company News

Interest in carbohydrate antigens grows with Siamab acquisition

...Deal" ). Boehringer has previously acquired partner companies. In September, Boehringer acquired oncolytic virus company ViraTherapeutics GmbH...
...companies had teamed up in 2016 to jointly develop an oncolytic virus platform and investigate ViraTherapeutics'...
...Platform" ). Lauren Martz, Associate Editor ST1 antibody-drug conjugate (ADC) Amal Therapeutics S.A. Boehringer Ingelheim GmbH Go Therapeutics Inc. Roche Siamab Therapeutics Inc. ViraTherapeutics GmbH...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...$10 million up front and $3 million in milestones. Last year, Boehringer Ingelheim GmbH acquired ViraTherapeutics...
...$3 million in preclinical milestones. AstraZeneca has an option to the viral candidates. May 2019 ViraTherapeutics...
...from the immune system and a modification to prevent viral neurotoxicity Preclinical NA Boehringer acquired ViraTherapeutics...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...treat infectious diseases Undisclosed 2018 ViraTherapeutics GmbH Cancer Oncolytic viruses Boehringer acquired chimeric oncolytic virus company ViraTherapeutics...
...modalities. In addition to the AMAL cancer vaccine platform, Boehringer acquired the oncolytic virus company ViraTherapeutics GmbH...
...two companies had a 2016 partnership to jointly develop an oncolytic virus platform and investigate ViraTherapeutics’...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$400 $800 $1,200 Allergan plc (NYSE:AGN) Bonti Inc. 9/14/18 $195 ND $195 Boehringer Ingelheim GmbH ViraTherapeutics GmbH...
BioCentury | Sep 14, 2018
Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

...2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP. ViraTherapeutics...
...the deal is about €210 million ($243 million), according to Boehringer. Under the 2016 deal, ViraTherapeutics...
...ViraTherapeutics GmbH, Innsbruck, Austria Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Mary Romeo VSV-GP Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund ViraTherapeutics GmbH...
BioCentury | Sep 13, 2018
Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

...2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP. ViraTherapeutics...
...the deal is about €210 million ($243 million), according to Boehringer. Under the 2016 deal, ViraTherapeutics...
...ViraTherapeutics' €3.6 million ($4 million) series A round in 2015. Mary Romeo Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund ViraTherapeutics GmbH...
BioCentury | Jun 9, 2017
Company News

Management tracks

...He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH...
Items per page:
1 - 10 of 14
BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

...commercial milestones. It acquired oncolytic virus company ViraTherapeutics GmbH...
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...with smaller deals for European biotechs in recent years. It acquired Austrian oncolytic virus developer ViraTherapeutics GmbH...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...the executive director of a life sciences consulting firm; Müller was head of CMC at ViraTherapeutics GmbH...
BioCentury | Aug 21, 2019
Company News

Interest in carbohydrate antigens grows with Siamab acquisition

...Deal" ). Boehringer has previously acquired partner companies. In September, Boehringer acquired oncolytic virus company ViraTherapeutics GmbH...
...companies had teamed up in 2016 to jointly develop an oncolytic virus platform and investigate ViraTherapeutics'...
...Platform" ). Lauren Martz, Associate Editor ST1 antibody-drug conjugate (ADC) Amal Therapeutics S.A. Boehringer Ingelheim GmbH Go Therapeutics Inc. Roche Siamab Therapeutics Inc. ViraTherapeutics GmbH...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

...$10 million up front and $3 million in milestones. Last year, Boehringer Ingelheim GmbH acquired ViraTherapeutics...
...$3 million in preclinical milestones. AstraZeneca has an option to the viral candidates. May 2019 ViraTherapeutics...
...from the immune system and a modification to prevent viral neurotoxicity Preclinical NA Boehringer acquired ViraTherapeutics...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...treat infectious diseases Undisclosed 2018 ViraTherapeutics GmbH Cancer Oncolytic viruses Boehringer acquired chimeric oncolytic virus company ViraTherapeutics...
...modalities. In addition to the AMAL cancer vaccine platform, Boehringer acquired the oncolytic virus company ViraTherapeutics GmbH...
...two companies had a 2016 partnership to jointly develop an oncolytic virus platform and investigate ViraTherapeutics’...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$400 $800 $1,200 Allergan plc (NYSE:AGN) Bonti Inc. 9/14/18 $195 ND $195 Boehringer Ingelheim GmbH ViraTherapeutics GmbH...
BioCentury | Sep 14, 2018
Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

...2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP. ViraTherapeutics...
...the deal is about €210 million ($243 million), according to Boehringer. Under the 2016 deal, ViraTherapeutics...
...ViraTherapeutics GmbH, Innsbruck, Austria Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Mary Romeo VSV-GP Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund ViraTherapeutics GmbH...
BioCentury | Sep 13, 2018
Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

...2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP. ViraTherapeutics...
...the deal is about €210 million ($243 million), according to Boehringer. Under the 2016 deal, ViraTherapeutics...
...ViraTherapeutics' €3.6 million ($4 million) series A round in 2015. Mary Romeo Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund ViraTherapeutics GmbH...
BioCentury | Jun 9, 2017
Company News

Management tracks

...He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH...
Items per page:
1 - 10 of 14